Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma

作者: M. Sherman , K. Burak , J. Maroun , P. Metrakos , J. J. Knox

DOI: 10.3747/CO.V18I5.952

关键词:

摘要: Globally, hepatocellular carcinoma (hcc) is the third most common cause of death from cancer, after lung and stomach cancer. The incidence hcc in Canada increasing expected to continue increase over next decade. Given high mortality rate associated with hcc, steps are required mitigate impact disease. To address this challenging situation, a panel 17 experts, representing gastroenterologists, hepatologists, hepatobiliary surgeons, medical oncologists, pathologists, radiologists across Canada, convened provide framework that, using an evidence-based approach, will assist clinicians optimizing management treatment hcc. recommendations, summarized here, were developed based on rigorous methodology pre-specified process that was overseen by steering committee. Specific topics identified committee delegated group content experts within expert panel, who then systematically reviewed literature topic drafted related recommendations. set recommendations for each assigned level evidence grade according levels out Centre Evidence-based Medicine, Oxford, United Kingdom. Agreement recommendation achieved consensus. Consensus defined as agreement two-thirds majority members panel. Recommendations subject iterative review modification until consensus could be achieved.?

参考文章(98)
Yamanoi A, Ono T, Nagasue N, Uchida M, Kohno H, Hayashi T, Yukaya H, Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Seminars in Oncology. ,vol. 24, ,(1997)
Kelly W Burak, Norman M Kneteman, An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): The Alberta HCC algorithm Canadian Journal of Gastroenterology & Hepatology. ,vol. 24, pp. 643- 650 ,(2010) , 10.1155/2010/410574
Yukihiro Koike, Yasushi Shiratori, Shinpei Sato, Shuntaro Obi, Takuma Teratani, Masatoshi Imamura, Haruhiko Yoshida, Shuichiro Shiina, Masao Omata, Des-γ-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma Cancer. ,vol. 91, pp. 561- 569 ,(2001) , 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N
Stephanie H Y Lau, Eric C H Lai, Wan-Yee Lau, The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Hepatobiliary & Pancreatic Diseases International. ,vol. 8, pp. 124- 133 ,(2009)
Puneeta Tandon, Guadalupe Garcia-Tsao, Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies Liver International. ,vol. 29, pp. 502- 510 ,(2009) , 10.1111/J.1478-3231.2008.01957.X
Laurence Christa, Marie-Thérèse Simon, Jean-Pierre Flinois, Rolf Gebhardt, Christian Brechot, Chantal Lasserre, Overexpression of glutamine synthetase in human primary liver cancer Gastroenterology. ,vol. 106, pp. 1312- 1320 ,(1994) , 10.1016/0016-5085(94)90024-8
Gaia Pocobelli, Linda S. Cook, Rollin Brant, Samuel S. Lee, Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis Liver International. ,vol. 28, pp. 1272- 1279 ,(2008) , 10.1111/J.1478-3231.2008.01704.X
Ghassan K. Abou-Alfa, Philip Johnson, Jennifer J. Knox, Marinela Capanu, Irina Davidenko, Juan Lacava, Thomas Leung, Bolorsukh Gansukh, Leonard B. Saltz, Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. ,vol. 304, pp. 2154- 2160 ,(2010) , 10.1001/JAMA.2010.1672
J Zucman-Rossi, S Benhamouche, C Godard, S Boyault, G Grimber, C Balabaud, A S Cunha, P Bioulac-Sage, C Perret, Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. ,vol. 26, pp. 774- 780 ,(2007) , 10.1038/SJ.ONC.1209824